Skip to main content
OpenTrials

Clinical trial condition

Blood-Borne Infections

Explore clinical trials studying Blood-Borne Infections. Study availability and eligibility vary by location and protocol.

8,277 public trials 443 recruiting studies
Refine in advanced search Browse all conditions

Blood-Borne Infections trial results

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination Tablet With Ribavirin for 12 Weeks in Treatment-naive Adults With Chronic HCV Genotype 3 Infection

NCT02413593

Conditions
Blood-Borne Infections, Chronic Disease, Communicable Diseases, +15 more
Locations
  • Calgary, Alberta, Canada
  • Edmonton, Alberta, Canada
  • Edmonton, Alberta, Canada
  • Vancouver, British Columbia, Canada
View all 15 locations
View Trial Details
Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Treatment-Experienced Subjects With Genotype 1 HCV Infection

NCT01768286

Conditions
Blood-Borne Infections, Chronic Disease, Chronic Hepatitis C Virus, +17 more
Locations
  • Phoenix, Arizona, United States
  • Tucson, Arizona, United States
  • La Jolla, California, United States
  • Los Angeles, California, United States
View all 53 locations
View Trial Details
Completed

Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection

NCT02480712

Conditions
Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +9 more
Locations
  • Birmingham, Alabama, United States
  • Los Angeles, California, United States
  • San Diego, California, United States
  • San Francisco, California, United States
View all 15 locations
View Trial Details
Completed

Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination in Participants With Chronic Hepatitis C Virus Infection

NCT02722837

Conditions
Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +9 more
Locations
  • Krasnoyarsk Regional Center of AIDS Prevention Krasnoyarsk, Russia
  • Central Research Institute of Epidemiology Moscow, Russia
  • Central Scientific-Research Institute of Epidemiology Moscow, Russia
  • City Clinical Hospital # 24 Moscow, Russia
View all 15 locations
View Trial Details
Completed

Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults

NCT01968551

Conditions
Acquired Immunodeficiency Syndrome, Blood-Borne Infections, Communicable Diseases, +14 more
Locations
  • Pueblo Family Physicians, Ltd. Phoenix, Arizona, United States
  • Pacific Oaks Medical Group Beverly Hills, California, United States
  • Kaiser Permanente Hayward, California, United States
  • Long Beach Education and Research Consultants Long Beach, California, United States
View all 62 locations
View Trial Details

Related conditions